First identified as a component in several smoking blends by Japanese laboratories back on 2012, EAM-2201 acts as a CB1
cannabinoid receptor full agonist with Ki
values of 1.0 nM for the central CB1
cannabinoid receptor and 2.6 nM for the periperal CB2
cannabinoid receptor. While EAM-2201 bind to both CB1
cannabinoid receptors, the compound tends to bind primarily to the CB1
cannabinoid receptor over the CB2
cannabinoid receptor. As previously stated EAM-2201 is considered to be a structural analog of AM-2201, differing only by the addition of an ethyl group at the 4 position of the naphthyl group.